BUZZ — Moderna retreats from 52 — week high, wiping out $10 bln in value
* Shares of Moderna fall 11.6% to $209.16, snapping a three-day winning streak and worst performer on the Nasdaq 100 * Stock on track for its biggest one-day drop since Aug 20, shedding $10 billion in market value if losses hold * Pullback follows a 52-week high of $242.29 on Thursday and a gain of about 20% over the previous three sessions * Shares are still up more than 50% over the past month and nearly tenfold from their 52-week low of $22.28 in November * Rally has been driven by the late-stage cancer vaccine trial data developed with Merck * Detailed data from the Moderna-Merck cancer vaccine trial is due at the ESMO Congress on October 24 * Earlier this month, Moderna joined the Nasdaq 100 index to replace Warner Bros Discovery * 6 of 25 brokerages rate Moderna's stock "buy" or higher, 15 rate it "hold" and four rate it "sell" or lower; their median price target is $130 — LSEG * Including session's move, MRNA up more than sevenfold YTD (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;)
* Shares of Moderna fall 11.6% to $209.16, snapping a three-day winning streak and worst performer on the Nasdaq 100 * Stock on track for its biggest one-day drop since Aug 20, shedding $10 billion in market value if losses hold * Pullback follows a 52-week high of $242.29 on Thursday and a gain of about 20% over the previous three sessions * Shares are still up more than 50% over the past month and nearly tenfold from their 52-week low of $22.28 in November * Rally has been driven by the late-stage cancer vaccine trial data developed with Merck * Detailed data from the Moderna-Merck cancer vaccine trial is due at the ESMO Congress on October 24 * Earlier this month, Moderna joined the Nasdaq 100 index to replace Warner Bros Discovery * 6 of 25 brokerages rate Moderna's stock "buy" or higher, 15 rate it "hold" and four rate it "sell" or lower; their median price target is $130 — LSEG * Including session's move, MRNA up more than sevenfold YTD (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;)